These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Margaroni M; Agallou M; Athanasiou E; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E Int J Nanomedicine; 2017; 12():6169-6184. PubMed ID: 28883727 [TBL] [Abstract][Full Text] [Related]
9. Multicomponent LBSap vaccine displays immunological and parasitological profiles similar to those of Leish-Tec® and Leishmune® vaccines against visceral leishmaniasis. de Mendonça LZ; Resende LA; Lanna MF; Aguiar-Soares RD; Roatt BM; Castro RA; Batista MA; Silveira-Lemos D; Gomes Jde A; Fujiwara RT; Rezende SA; Martins-Filho OA; Corrêa-Oliveira R; Dutra WO; Reis AB; Giunchetti RC Parasit Vectors; 2016 Aug; 9(1):472. PubMed ID: 27577735 [TBL] [Abstract][Full Text] [Related]
10. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C Front Immunol; 2018; 9():465. PubMed ID: 29599776 [TBL] [Abstract][Full Text] [Related]
11. Recombinant endonuclease III protein from Leishmania infantum associated with Th1-type adjuvants is immunogenic and induces protection against visceral leishmaniasis. Lage DP; Machado AS; Freitas CS; Vale DL; Linhares FP; Cardoso JMO; Oliveira-da-Silva JA; Ramos FF; Pereira IAG; Ludolf F; Tavares GSV; Bandeira RS; Oliveira JS; Menezes-Souza D; Duarte MC; Galdino AS; Christodoulides M; Chávez-Fumagalli MA; Roatt BM; Martins VT; Coelho EAF Mol Immunol; 2023 Mar; 155():79-90. PubMed ID: 36731193 [TBL] [Abstract][Full Text] [Related]
12. A specific Leishmania infantum polyepitope vaccine triggers Th1-type immune response and protects against experimental visceral leishmaniasis. Lopes Valentim Di Paschoale Ostolin T; Rodrigues Gusmão M; Augusto Siqueira Mathias F; Mirelle de Oliveira Cardoso J; Mendes Roatt B; Dian de Oliveira Aguiar-Soares R; Conceição Ruiz J; de Melo Resende D; Cristiane Fortes de Brito R; Barbosa Reis A Cell Immunol; 2022 Oct; 380():104592. PubMed ID: 36084402 [TBL] [Abstract][Full Text] [Related]
13. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis. Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943 [TBL] [Abstract][Full Text] [Related]
14. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis. de Oliveira Emerick S; Vieira de Carvalho T; Meirelles Miranda B; Carneiro da Silva A; Viana Fialho Martins T; Licursi de Oliveira L; de Almeida Marques-da-Silva E Vaccine; 2021 Jan; 39(2):282-291. PubMed ID: 33309484 [TBL] [Abstract][Full Text] [Related]
15. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911 [TBL] [Abstract][Full Text] [Related]
16. Intranasal but not subcutaneous vaccination with LaAg allows rapid expansion of protective immunity against cutaneous leishmaniasis. Pereira Silva Bezerra I; Amaral Abib M; Rossi-Bergmann B Vaccine; 2018 Apr; 36(18):2480-2486. PubMed ID: 29599090 [TBL] [Abstract][Full Text] [Related]
18. A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis. Martins VT; Duarte MC; Chávez-Fumagalli MA; Menezes-Souza D; Coelho CS; de Magalhães-Soares DF; Fernandes AP; Soto M; Tavares CA; Coelho EA Parasit Vectors; 2015 Jul; 8():363. PubMed ID: 26160291 [TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum. Bras-Gonçalves R; Petitdidier E; Pagniez J; Veyrier R; Cibrelus P; Cavaleyra M; Maquaire S; Moreaux J; Lemesre JL Infect Genet Evol; 2014 Jun; 24():1-14. PubMed ID: 24614507 [TBL] [Abstract][Full Text] [Related]
20. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]